Search Results - "Miller, Antonius A"

A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma by Lycan, Thomas W, Pardee, Timothy S, Petty, William J, Bonomi, Marcelo, Alistar, Angela, Lamar, Zanetta S, Isom, Scott, Chan, Michael D, Miller, Antonius A, Ruiz, Jimmy

“…Small cell lung cancer (SCLC) is a common lung cancer which presents with extensive stage disease at time of diagnosis in two-thirds of patients. For treatment…”
Get full text

Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age by Ruiz, Jimmy, Miller, Antonius A., Tooze, Janet A., Crane, Sandrine, Petty, William J., Gajra, Ajeet, Klepin, Heidi D.

“…Improved assessment strategies are needed to individualize treatment for adults of all ages receiving palliative chemotherapy for non-small cell lung cancer…”
Get full text

Randomized Phase II Trial of Induction Chemotherapy Followed by Concurrent Chemotherapy and Dose-Escalated Thoracic Conformal Radiotherapy (74 Gy) in Stage III Non–Small-Cell Lung Cancer: CALGB 30105 by Socinski, Mark A, Blackstock, A William, Bogart, Jeffrey A, Wang, Xiaofei, Munley, Michael, Rosenman, Julian, Gu, Lin, Masters, Gregory A, Ungaro, Peter, Sleeper, Arthur, Green, Mark, Miller, Antonius A, Vokes, Everett E

“…To evaluate 74 Gy thoracic radiation therapy (TRT) with induction and concurrent chemotherapy in stage IIIA/B non-small-cell lung cancer (NSCLC). Patients with…”
Get full text

Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301 by MILLER, Antonius A, MURRY, Daryl J, LEWIS, Lionel D, FAKIH, Marwan G, EDELMAN, Martin J, MILLARD, Fred, FRANK, Richard C, HOHL, Raymond J, RATAIN, Mark J, OWZAR, Kouros, HOLLIS, Donna R, KENNEDY, Erin B, ABOU-ALFA, Ghassan, DESAI, Apurva, HWANG, Jimmy, VILLALONA-CALERO, Miguel A, DEES, E. Claire

“…We sought to characterize the pharmacokinetics (PK) and determine a tolerable dose of oral sorafenib in patients with hepatic or renal dysfunction. Patients…”
Get full text

Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years? by Lally, Brian E., Urbanic, James J., Blackstock, A. William, Miller, Antonius A., Perry, Michael C.

“…Learning Objectives After completing this course, the reader will be able to: Discuss the currently available SCLC treatment options. Describe the benefits of…”
Get full text

Single-Agent Versus Combination Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730) by Lilenbaum, Rogerio C, Herndon, 2nd, James E, List, Marcy A, Desch, Chris, Watson, Dorothy M, Miller, Antonius A, Graziano, Stephen L, Perry, Michael C, Saville, Wayne, Chahinian, Philippe, Weeks, Jane C, Holland, Jimmie C, Green, Mark R

“…We compared the efficacy of combination chemotherapy versus single-agent therapy in patients with advanced non-small-cell lung cancer. A total of 561 eligible…”
Get full text

Phase I and Pharmacokinetic Study of Angiotensin-(1-7), an Endogenous Antiangiogenic Hormone by JEFFREY PETTY, W, MILLER, Antonius A, MCCOY, Thomas P, GALLAGHER, Patricia E, TALLANT, E. Ann, TORTI, Frank M

“…Purpose: Angiotensin-(1-7) [Ang-(1-7)] is an endogenous peptide hormone of the renin-angiotensin system with antiproliferative and antiangiogenic properties…”
Get full text

Randomized Phase II Study of Cisplatin With Gemcitabine or Paclitaxel or Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Stage IIIB Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Study 9431 by VOKES, Everett E, HERNDON, James E, CRAWFORD, Jeffrey, LEOPOLD, Kenneth A, PERRY, Michael C, MILLER, Antonius A, GREEN, Mark R

“…To evaluate new drugs in combination with cisplatin in unresectable stage III non-small-cell lung cancer, Cancer and Leukemia Group B (CALGB) conducted a…”
Get full text

Phase II Trial of Angiotensin-(1-7) for the Treatment of Patients with Metastatic Sarcoma by Savage, Paul D., Lovato, James, Brosnihan, K. Bridget, Miller, Antonius A., Petty, W. Jeffrey

“…Background. Angiotensin-(1-7) [Ang-(1-7)] is an endogenous antiangiogenic hormone with anticancer activity. In a phase I study of Ang-(1-7), two of three…”
Get full text

Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732 by NIELL, Harvey B, HERNDON, James F, ELLERTON, John, VOKES, Everett E, GREEN, Mark R, MILLER, Antonius A, WATSON, Dorothy M, SANDLER, Alan B, KELLY, Karen, MARKS, Kandolph S, PERRY, Michcal C, AUSARI, Rafat H, OTTERSON, Grefory

“…To determine, in a randomized comparison, whether the addition of paclitaxel to etoposide and cisplatin improves the time to progression and overall survival…”
Get full text

Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or Renal Dysfunction: CALGB 60101 by MILLER, Antonius A, MURRY, Daryl J, LICHTMAN, Stuart M, RATAIN, Mark J, OWZAR, Kouros, HOLLIS, Donna R, LEWIS, Lionel D, KINDLER, Hedy L, MARSHALL, John L, VILLALONA-CALERO, Miguel A, EDELMAN, Martin J, HOHL, Raymond

“…We investigated dose and pharmacokinetics of erlotinib in patients with hepatic dysfunction or renal dysfunction. Patients were assigned to one of three…”
Get full text

Image guided radiation therapy may result in improved local control in locally advanced lung cancer patients by Kilburn, Jeremy M., Soike, Michael H., Lucas, John T., Ayala-Peacock, Diandra, Blackstock, William, Isom, Scott, Kearns, William T., Hinson, William H., Miller, Antonius A., Petty, William J., Munley, Michael T., Urbanic, James J.

“…Image guided radiation therapy (IGRT) is designed to ensure accurate and precise targeting, but whether improved clinical outcomes result is unknown. A…”
Get full text

Prospective Evaluation of the Relationship of Patient Age and Paclitaxel Clinical Pharmacology: Cancer and Leukemia Group B (CALGB 9762) by LICHTMAN, Stuart M, HOLLIS, Donna, PARISE, Robert A, RATAIN, Mark J, EGORIN, Merrill J, MILLER, Antonius A, ROSNER, Gary L, RHOADES, Chris A, LESTER, Eric P, MILLARD, Frederick, BYRD, John, CULLINAN, Stephen A, ROSEN, D. Marc

“…To prospectively evaluate the pharmacokinetics and toxicity profile of paclitaxel in relation to patient age in adults > or = 55 years old. Paclitaxel was…”
Get full text

Reverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of hypoxia inducible factor-1α in vascular sarcomas by Petty, W Jeffrey, Aklilu, Mebea, Varela, Victor A, Lovato, James, Savage, Paul D, Miller, Antonius A

“…In a phase I study of angiotensin-(1-7) [Ang-(1-7)], clinical benefit was associated with reduction in plasma placental growth factor (PlGF) concentrations…”
Get full text

Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance) by Ready, Neal E, Pang, Herbert H, Gu, Lin, Otterson, Gregory A, Thomas, Sachdev P, Miller, Antonius A, Baggstrom, Maria, Masters, Gregory A, Graziano, Stephen L, Crawford, Jeffrey, Bogart, Jeffrey, Vokes, Everett E

“…To evaluate the efficacy of maintenance sunitinib after chemotherapy for small-cell lung cancer (SCLC). The Cancer and Leukemia Group B 30504 trial was a…”
Get full text

Low-Dose CT Lung Cancer Screening Practices and Attitudes among Primary Care Providers at an Academic Medical Center by Lewis, Jennifer A, Petty, W Jeffrey, Tooze, Janet A, Miller, David P, Chiles, Caroline, Miller, Antonius A, Bellinger, Christina, Weaver, Kathryn E

“…Low-dose computed tomography (LDCT) screening reduces lung cancer-specific and overall mortality. We sought to assess lung cancer screening practices and…”
Get full text

Differences in Clinical Trial Patient Attributes and Outcomes According to Enrollment Setting by LAMONT, Elizabeth B, LANDRUM, Mary Beth, MILLER, Antonius A, CLAMON, Gerald H, ELIAS, Anthony D, MCCLAY, Edward F, VOKES, Everett E, MCNEIL, Barbara J, KEATING, Nancy L, ARCHER, Laura, LAN LAN, STRAUSS, Gary M, LILENBAUM, Rogerio, NIELL, Harvey B, HERBERT MAURER, L, KOSTY, Michael P

“…During the last 25 years, National Cancer Institute (NCI) cooperative trial groups have extended trial networks from academic centers to include certain…”
Get full text

A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871 by LEWIS, Lionel D, MILLER, Antonius A, OTTERSON, Gregory A, MILLARD, Frederick, RATAIN, Mark J, ROSNER, Gary L, DOWELL, Jonathan E, VALDIVIESO, Manuel, RELLING, Mary V, EGORIN, Merrill J, BIES, Robert R, HOLLIS, Donna R, LEVINE, Ellis G

“…Purpose: Increased clearance of drugs, such as oral cyclosporine, that are CYP3A and/or ABCB1 (P-gp/MDR1) substrates was reported in African-American compared…”
Get full text

Similar Outcomes Between African American and Non–African American Patients With Extensive-Stage Small-Cell Lung Carcinoma: Report From the Cancer and Leukemia Group B by BLACKSTOCK, A. William, HERNDON, James E, PASKETT, Electra D, MILLER, Antonius A, LATHAN, Christopher, NIELL, Harvey B, SOCINSKI, Mark A, VOKES, Everett E, GREEN, Mark R

“…Among patients with small-cell lung carcinoma, African Americans have lower survival rates than non-African Americans. We investigated whether the disparity in…”
Get full text

Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment by Kilburn, Jeremy M, Kuremsky, Jeffrey G, Blackstock, A. William, Munley, Michael T, Kearns, William T, Hinson, William H, Lovato, James F, Miller, Antonius A, Petty, William J, Urbanic, James J

“…Abstract Background and purpose Management for in-field failures after thoracic radiation is poorly defined. We evaluated SBRT as an initial or second course…”
Get full text